| Autor: |
Valsecchi AA; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 Turin, Italy., Dionisio R; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 Turin, Italy., Panepinto O; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 Turin, Italy., Paparo J; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 Turin, Italy., Palicelli A; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy., Vignani F; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 Turin, Italy., Di Maio M; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 Turin, Italy. |
| Abstrakt: |
In prostate cancer (PC), the presence of BRCA somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of BRCA mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of BRCA mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic BRCA1 and/or BRCA2 mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic BRCA1/2 mutation, respectively. Somatic mutations are more common than germline and BRCA2 are more common than BRCA1 mutations; the frequency of mutations is higher in the metastatic setting. Despite that BRCA testing in PC is now standard in clinical practice, several open questions remain. |
